Education
About Us
Working with TipRanks
Follow Us
Atricure, Inc. (ATRC)
:ATRC
ATRC Stock Chart & Stats
$32.90
$0.79(2.42%)
At close: 4:00 PM EST
$32.90
$0.79(2.42%)
Day’s Range― - ―
52-Week Range$28.29 - $43.11
Previous CloseN/A
Volume180.64K
Average Volume (3M)548.70K
Market Cap
$1.65B
Enterprise Value$1.62B
Total Cash (Recent Filing)$147.87M
Total Debt (Recent Filing)$73.73M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Feb 24, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding49,716,988
10 Day Avg. Volume514,129
30 Day Avg. Volume548,702
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)3.11
Price to Sales (P/S)3.08
P/FCF Ratio-127.52
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit4.19
Enterprise Value/Ebitda-259.54
Forecast
1Y Price Target
$52.60Price Target Upside59.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$530.70M
Bulls Say, Bears Say
Bulls Say
Guidance And ProjectionsThe company raised its revenue and adjusted EBITDA guidance, reflecting strong performance and conservative projections.
Product LaunchesThere is potential for new product launches to drive additional revenue and EBITDA upside.
Revenue GrowthATRC reported revenue and adjusted EBITDA well ahead of estimates, driven by continued growth in EnCompass and AtriClip products.
Bears Say
MIS Segment DeclineThe company is seeing strong growth in the open segment and a decline in MIS due to PFA pressure.
Atricure News
ATRC FAQ
What was Atricure, Inc.’s price range in the past 12 months?
Atricure, Inc. lowest stock price was $28.29 and its highest was $43.11 in the past 12 months.
What is Atricure, Inc.’s market cap?
Atricure, Inc.’s market cap is $1.65B.
When is Atricure, Inc.’s upcoming earnings report date?
Atricure, Inc.’s upcoming earnings report date is Feb 24, 2026 which is in 96 days.
How were Atricure, Inc.’s earnings last quarter?
Atricure, Inc. released its earnings results on Oct 29, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.112 by $0.102.
Is Atricure, Inc. overvalued?
According to Wall Street analysts Atricure, Inc.’s price is currently Undervalued.
Does Atricure, Inc. pay dividends?
Atricure, Inc. does not currently pay dividends.
What is Atricure, Inc.’s EPS estimate?
Atricure, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Atricure, Inc. have?
Atricure, Inc. has 49,716,988 shares outstanding.
What happened to Atricure, Inc.’s price movement after its last earnings report?
Atricure, Inc. reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.112. Following the earnings report the stock price went down -3.809%.
Which hedge fund is a major shareholder of Atricure, Inc.?
Currently, no hedge funds are holding shares in ATRC
Atricure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.60 (59.88% Upside)
$52.60 (59.88% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $473.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.94%
12-Months-Change
Fundamentals
Return on Equity
-6.11%
Trailing 12-Months
Asset Growth
3.31%
Trailing 12-Months
Company Description
Atricure, Inc.
AtriCure, Inc. is a medical device company specializing in innovative solutions for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. Founded in 2000 and headquartered in Mason, Ohio, AtriCure develops and manufactures a range of products specifically designed to improve patient outcomes in heart surgery. Its core offerings include energy-based devices for cardiac ablation procedures, as well as accessories and surgical tools that enhance the effectiveness of these interventions. AtriCure operates primarily within the cardiology and surgical sectors, focusing on advancing minimally invasive techniques.
ATRC Company Deck
ATRC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance with significant revenue growth, improved profitability, and successful product launches across key segments. Despite some challenges in the minimally invasive ablation and hybrid therapy markets, the company is well-positioned with a solid cash position and raised guidance for the year.View all ATRC earnings summariesATRC Stock 12 Month Forecast
Average Price Target
$52.60
▲(59.88% Upside)
Technical Analysis
Ownership Overview
3.54% Insiders
39.89% Mutual Funds
24.23% Other Institutional Investors
16.49% Public Companies and
Individual Investors